Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novartis 4Q Results | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Novartis 4Q Results

Revenue growth in the quarter driven by Entresto, Kesimpta, Kisqali, Cosentyx, and Leqvio, offset by declines for Lucentis and Gilenya.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Image: Novartis

Novartis

4Q Revenues: $13.2 billion (+15%)

4Q Earnings: $2.8 billion (-67%)

FY Revenues: $50.3 billion (+11%)

FY Earnings: $11.9 billion (-24%)

Comments: Sales growth in the quarter was mainly driven by Entresto with $2.2 billion in sales, up 33%, Kesimpta sales of $950 million, up 48%, Kisqali sales of $902 million, up 48%, Cosentyx sales of $1.6 billion, up 22%, and Leqvio sales of $223 million, up 81%, partly offset by declines mainly for Lucentis, with sales down 30% to $210 million, and Gilenya down 29% to $109 million, due to generic competition.

Earnings reflect R&D investments in 2024 including the acquisition of Kate Therapeutics, Mariana Oncology, IFM Due, MorphoSys AG, Calypso Biotech BV, and SanReno Therapeutics. Additionally, as the Sandoz spin-off was completed on October 2023, there were no operating results in 2024 related to discontinued operations.

Read more about Novartis’ acquisitions in 2024 here.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics